Crenolanib
Maintenance therapy for FLT3-ITD mutated AML post-allogeneic hematopoietic stem cell transplant (HSCT)
Phase 3Active
Key Facts
Indication
Maintenance therapy for FLT3-ITD mutated AML post-allogeneic hematopoietic stem cell transplant (HSCT)
Phase
Phase 3
Status
Active
Company
About AROG Pharmaceuticals
AROG Pharmaceuticals is a private, pre-revenue biotech advancing crenolanib, a selective FLT3 inhibitor, for maintenance therapy in high-risk AML patients following stem cell transplant. The company is positioned as 'Phase III-ready,' with a clear regulatory path to address a significant unmet need in a poor-prognosis population. Its strategy hinges on demonstrating that crenolanib can improve relapse-free and overall survival in this setting, potentially capturing a meaningful share of the growing AML market. Success in the planned Phase III trial would be a major value inflection point for the company.
View full company profile